TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02796404

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Homebased cardiac rehabilitation program
Description: homebased cardiac rehabilitation program with monitoring vest Nuubo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional cardiac rehabilitation program
Description: multidisciplinary intervention in cardiac rehabilitation gym

Intervention type: OTHER
Group type: OTHER
Intervention: Traditional cardiac rehabilitation program
Description: multidisciplinary intervention in cardiac rehabilitation gym
Study: NCT05573594

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle Energy Technique
Description: The Janda method (Post isometric relaxation PIR Technique), one of the Muscle Energy Techniques, was used on m.piriformis, m.quadratus lumborum, m.hamstring, m.psoas major muscles in the study group. First, the dysfunctional muscle was stretched passively by the physiotherapist up to the movement barrier, and 5-7 seconds of isometric muscle contraction in the opposite direction was requested from the patient at the barrier. This practice was continued until muscle tension or joint dysfunction disappeared.~All participants performed standard home exercises consisting of stretching and strengthening. These exercises were taught to the participants by the physiotherapist in the first treatment session, and when they came to each treatment session, it was questioned whether they did it or not, and a control chart was created for exercise follow-up.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional physical therapy and rehabilitation
Description: In the content of conventional physiotherapy program for both groups; Hot Pack (20 min), Ultrasound (ITO brand 1 MHz and 1.5 W/cm2, 5 min), Transcutaneous Electrical Nerve Stimulation (TENS, 50-100 Hz, 20 min) and standard home exercises were included. The program went 5 times a week, 10 consecutive sessions. Each session lasted an average of 45 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional physical therapy and rehabilitation
Description: In the content of conventional physiotherapy program for both groups; Hot Pack (20 min), Ultrasound (ITO brand 1 MHz and 1.5 W/cm2, 5 min), Transcutaneous Electrical Nerve Stimulation (TENS, 50-100 Hz, 20 min) and standard home exercises were included. The program went 5 times a week, 10 consecutive sessions. Each session lasted an average of 45 minutes.
Study: NCT01059604

Intervention type: DRUG
Intervention: Sumatriptan
Description: Sumatriptan

Intervention type: DRUG
Intervention: Naratriptan
Description: Naratriptan

Intervention type: DRUG
Intervention: Sumatriptan-naproxen combination
Description: Sumatriptan-naproxen combination
Study: NCT01746992

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide 750mg/m2
Description: day 1 in both arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 750mg/m2
Description: day 1 in both arms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine 1.4mg/m2
Description: day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine 1.4mg/m2
Description: day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin 50mg/m2
Description: day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone 60mg/m2
Description: day1-day5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone 60mg/m2
Description: day1-day5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide 2000mg/m2
Description: day 22-day 24

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pirarubicin 50mg/m2
Description: day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pirarubicin 25mg/m2
Description: day 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide phosphate 100mg/m2
Description: day 22-day 24

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate 1500mg/m2
Description: day 43
Study: NCT01545362

Intervention type: PROCEDURE
Intervention: Total knee arthroplasty
Description: Total knee arthroplasty
Study: NCT02162693

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal progenitor cells
Description: Administrated for intra-articular injection
Study: NCT02458651

Intervention type: OTHER
Intervention: No intervention
Description: No intervention administered in this study
Study: NCT02162693

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Hyaluronate
Study: NCT02458651

Intervention type: OTHER
Intervention: No intervention
Description: No intervention administered in this study

Intervention type: OTHER
Intervention: No intervention
Description: No intervention administered in this study

Intervention type: OTHER
Intervention: No intervention
Description: No intervention administered in this study

Intervention type: OTHER
Intervention: No intervention
Description: No intervention administered in this study

Intervention type: OTHER
Intervention: No intervention
Description: No intervention administered in this study
Study: NCT01454336

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cell injection
Description: MSCs introduced into portal vein
Study: NCT01668147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C] desmethyl-loperamide
Description: IV administration of 10-14 mCi of \[11C\] desmethyl-loperamide with PET/CT imaging

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [11C] desmethyl-loperamide
Description: IV administration of 10-14 mCi of \[11C\] desmethyl-loperamide with PET/CT imaging

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [11C] desmethyl-loperamide
Description: IV administration of 10-14 mCi of \[11C\] desmethyl-loperamide with PET/CT imaging

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control - no pretreatment
Description: Session 1: IV administration of 10-14 mCi \[11C\] desmethyl-loperamide (dLop) with PET/CT imaging and brain MRI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral ritonavir
Description: Session 2: Pretreatment with oral ritonavir for 3 days followed by IV administration of 10-14 mCi \[11C\]dLop with PET/CT imaging and brain MRI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral efavirenz
Description: Session 3: Pretreatment with oral efavirenz for 14 days followed by IV administration of 10-14 mCi \[11C\]dLop with PET/CT imaging and brain MRI
Study: NCT00421863

Intervention type: DRUG
Group type: OTHER
Intervention: Triatec HCT 5
Description: Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).

Intervention type: DRUG
Group type: OTHER
Intervention: Lasix 25
Description: Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).

Intervention type: DRUG
Group type: OTHER
Intervention: Lasix 25
Description: Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
Study: NCT03498755

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conditional cash transfer
Description: Participants will receive a conditional cash transfer to support their fish smoking business. The payment will be conditional on their participation in entrepreneurship trainings and the use of the investment into their fish smoking business.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Entrepreneurship training
Description: Entrepreneurship training will focus on commonly lacking business knowledge, with an emphasis on establishing fundamental entrepreneurial skills (i.e., customer care, accounting), sound business management and decision-making, building strong and sustainable business relationships, and encouraging the use of loans for their intended purposes. This training will be introduced during the credit and savings group (CSG) meetings that will occur twice per month.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Market price information
Description: Average market prices for fresh and processed fish at community, district, and regional markets will be disseminated via audio message calls (using Viamo's Infoline platform) to the mobile phones of women with the price information in their preferred language. These market prices will be collected twice weekly by Viamo field enumerators and sent to regional coordinators for validation. A second, independent validation will be carried out to ensure that there are no discrepancies.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Improved smoke ovens
Description: Local private sector artisans will construct and serve as suppliers of the new ovens. The promotion, uptake and impact of these improved Ahotor ovens will be tested among study participants. Awareness-raising workshops held in each community will promote the Ahotor in concert with a public retrofitting of a Chorkor stove. Immediately following this event, one month later, and three months later, study participants will receive additional one-on-one counseling to provide further support on the proper use of the smoke oven, as well as on optimal handling and smoking practices to enhance product quality.
Study: NCT02040792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-4208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-4208
Study: NCT00876980

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nasal Continuous Positive Airway Pressure
Description: A standard treatment for OSA. A portable machine delivers positive pressure through a mask to the upper airway during sleep at night.
Study: NCT00052429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT06339229

Intervention type: OTHER
Intervention: proteinuria
Description: dipstick proteinuria values negative, trace, 1+, and ≥2+
Study: NCT03335631

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Moderate intensity mixed-modality exercise 4-5 days per week, with a target of 60 minutes per session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Moderate intensity mixed-modality exercise 4-5 days per week, with a target of 60 minutes per session.
Study: NCT04133779

Intervention type: PROCEDURE
Intervention: neurological examination, Kurtzke EDSS, Barthel scale, ecocolor-Doppler
Description: For the subjects diagnosed with MS (group A), who did not need to be in a period of clinical relapse of the disease (at least 30 days from the last clinical relapse), the duration and the form of the disease was indicated (CIS, RR, SP or PP). The Investigator has submitted these subjects to a neurological examination which included the standard neurological examination, the Kurtzke EDSS (Kurtzke Expanded Disability Status Scale) comprising the functional systems of Kurtzke and the Barthel scale. After completing the selection phase following the previous examinations, the subjects were directed towards the qualified practitioner for the ecocolor-Doppler examination which was performed in blind.
Study: NCT02040792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-4208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-4208

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04133779

Intervention type: PROCEDURE
Intervention: neurological evaluation, ecocolor-Doppler
Description: For the subjects affected by OND and ONDi, as in the groups C and D respectively, the Investigator has performed, beside the anamnesis and the physical examination, a specific neurological evaluation which included the compilation of the Barthel scale for the disability evaluation. After completing the selection phase following the previous examinations, the subjects were directed towards the qualified practitioner for performing the ecocolor-Doppler examination which was performed in blind.
Study: NCT00451997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gleevec
Description: 600 mg (capsules) by mouth once daily
Study: NCT04133779

Intervention type: PROCEDURE
Intervention: neurological evaluation, ecocolor-Doppler
Description: For the subjects affected by OND and ONDi, as in the groups C and D respectively, the Investigator has performed, beside the anamnesis and the physical examination, a specific neurological evaluation which included the compilation of the Barthel scale for the disability evaluation. After completing the selection phase following the previous examinations, the subjects were directed towards the qualified practitioner for performing the ecocolor-Doppler examination which was performed in blind.

Intervention type: PROCEDURE
Intervention: medical history, vital signs, ecocolor-Doppler
Description: For the healthy subjects (HC) of the group B, the Investigator has solely performed the medical history and a check of the vital signs, reporting the demographic and clinical data of the subjects. After completing the selection phase following the previous examinations, the subjects were directed towards the qualified practitioner for the ecocolor-Doppler examination which was performed in blind.
Study: NCT02711670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chlorthalidone
Study: NCT04094090

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PXL-330 Platinum device for crosslinking with Peschke riboflavin solution
Description: Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea
Study: NCT00451997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ara-C
Description: 10 mg as an injection under the skin daily for 21 days of every 28 day cycle
Study: NCT00504348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Start at the standard starting dose of 0.075mg/kg/day divided into two doses, then adjust doses based on clinical response and tolerability, but maintain whole blood trough levels between 5 to 10 ng/mL and total daily doses equal to or below 0.3mg/kg.
Study: NCT02711670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Study: NCT01654497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexanabinol
Description: Dexanabinol: intravenous infusion over 3 hours, weekly (i.e., Day 1, 8, 15 and 22 of a 28-day cycle)~Nine dosing cohorts are planned, with the option to enroll additional cohorts based on safety and PK data.~Dose Level 1: 2 mg/kg~Dose Level 2: 4 mg/kg~Dose Level 3: 8 mg/kg~Dose Level 4: 16 mg/kg~Dose Level 5: 24 mg/kg~Dose Level 6: 28 mg/kg~Dose Level 7: 36 mg/kg~Dose Level 8: 40 mg/kg~Dose Level 9: 44 mg/kg
Study: NCT02949674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: It will be used as a analgesic dose in surgical site before surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: It will be used as a analgesic dose in surgical site before surgery.
Study: NCT04674852

Intervention type: DEVICE
Group type: OTHER
Intervention: Research Marker
Description: The research marker is a cylindrical-shaped marker made of an FDA-approved material that can be seen by ultrasound.
Study: NCT00370786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Study: NCT02954835

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prevena
Description: Prevena is a sterile silver dressing. On top of the silver dressing is an adhesive plastic, which is connected to a therapy unit through a short length suction tube.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Dressing
Description: Sterile gauze dressing secured by tape.
Study: NCT03711552

Intervention type: OTHER
Intervention: ObsQoR-11
Description: Quality of recovery questionnaire

Intervention type: OTHER
Intervention: QoR-15
Description: Quality of recovery questionnaire
Study: NCT03241797

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS-FNA
Description: Once the lesion was evaluated by EUS, the echoendoscopist would select the shortest pathway, while avoiding blood vessels, to reach the lesion. Under real-time visualization, slow-pull technique and suction technique were used to punctured each lesions. The specimens were expelled onto glass slides, and then prepared for histological and cytological examinations.
Study: NCT02444637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Study: NCT00709891

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cobas® 4800 HPV Test
Study: NCT02128646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXPAREL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXPAREL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic abdominal hernia repair

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic abdominal hernia repair

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: an open surgery for abdominal hernia repair

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: an open surgery for abdominal hernia repair
Study: NCT03839472

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CBI
Description: CBI with 5 liters normal saline in 1 liter increments up to 2 hours after TURBT procedure.
Study: NCT03699124

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FD MVA-BN
Description: Vaccinations with a 0.5 mL dose of vaccine containing at least 0.5 x 10E8 Infectious Units (Inf.U)
Study: NCT00659685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: ODT, single-dose, fasting
Study: NCT00659685

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zofran ODT
Study: NCT03174860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Potassium 50mg Tab
Description: A 50 mg tablet of the medication to be taken one hour before initiation of endodontic treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo will be taken one hour before initiation of endodontic treatment.
Study: NCT04098926

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Dose-integrated accelerated EBRT in pN0 breast cancer
Description: WBI: 5 x 5.7Gy Thoracic wall: 5 x 5.7Gy R0 boost: 5 x 6.5Gy R1 boost: 5 x 6.9Gy
Study: NCT00421863

Intervention type: DRUG
Group type: OTHER
Intervention: Micardis 80 mg
Description: Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).

Intervention type: DRUG
Group type: OTHER
Intervention: Micardis 80 mg
Description: Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).

Intervention type: DRUG
Group type: OTHER
Intervention: Micardis plus 80/12.5
Description: Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).

Intervention type: DRUG
Group type: OTHER
Intervention: Micardis plus 80/12.5
Description: Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
Study: NCT00864565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl 25 μg/h transdermal system, single application
Description: A: Experimental Subjects received Corium International, Inc formulated products

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duragesic 25 μg/h transdermal system single application
Description: B: Active comparator Subjects received Jassen Pharmaceutica Products, L.P. formulated products
Study: NCT03888885

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sport Education Model
Description: A total number of 25 lecturers participated in the 12-hour CPD workshop on Sport Education curriculum on June 2018. The content of the workshop focused on the development of a Sport Education season, the changing roles of teachers and students, the assessment of personal and social responsibility, and the application of sport education season and related pedagogies on handball, badminton, swimming and physical conditioning. The Sport Education courseware and class materials were then designed by the eligible lecturers. The intervention was lasted for 10-lesson, 1-day per week and the duration for each lesson was around 90 minutes. The specific five phases in Sport Education model of team selection, teacher-directed, pre-season, formal competition and cumulating event were included. The eligible lecturers led the lessons according to the designated course wares and lesson plans for each sport.
Study: NCT04244175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVL-865
Description: Participants will receive CVL-865 tablets orally BID up to the maximum dose of 7.5 mg BID or 25 mg BID during the treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVL-865
Description: Participants will receive CVL-865 tablets orally BID up to the maximum dose of 7.5 mg BID or 25 mg BID during the treatment period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive CVL-865 matched placebo tablet orally BID during the treatment period.
Study: NCT02772250

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: telephone re-education(TRE)
Description: Subjects who are randomized into this group receive regular instructions at the time of their appointment to discuss colonoscopy (a nurse provides education of 5 minutes and meanwhilet sent a bookle to the patient) and a TRE which was conducted by one investigator at 15:00-17:00 on the day before colonoscopy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: face-to-face re-education (FFRE)
Description: Subjects who are randomized into this group receive regular instructions on the day of their appointment to discuss colonoscopy and also a FFRE which was conducted by a investigator on the same-day of procedure at hospital.
Study: NCT03147092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Captopril 25Mg, Hydrochlorothiazide 25Mg Oral Tablet,
Description: Treatment of hypertensive subjects
Study: NCT04098926

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Dose-integrated accelerated EBRT in pN+ breast cancer
Description: WBI: 5 x 5.7Gy Thoracic wall: 5 x 5.7Gy R0 boost: 5 x 6.5Gy R1 boost: 5 x 6.9Gy Lymph node region: 5 x 5.4Gy
Study: NCT03147092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atenolol
Description: Treatment of hypertensive subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan potassium 50mg
Description: Treatment of hypertensive subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: Treatment of hypertensive subjects